Healthcare professionals and patients should be extremely cautious before prescribing or using these medications, and focus on safe, evidence-based dietary and lifestyle strategies for weight loss and metabolic health as first, second, and third-line treatment
Until recently they have had little support from the two dominant GLP-1 drug makers, Novo Nordisk and Eli Lilly who have not considered addition a high prioroty (Sheridan)
Patients cant see whether they qualify, what the price is, or what the program contains until they have committed an identity to the platform
You will also find information on treatment, key warning signs to look out for, and information about how long the symptoms may last
A Mississippi doctor had his license suspended in 2023 for prescribing Ozempic through instant messaging with no exam